CYFIP2 Polyclonal Antibody

    • Catalog No.:YT5782
    • Applications:WB;ELISA
    • Reactivity:Human;Mouse;Rat
      • Target:
      • CYFIP2
      • Fields:
      • >>Regulation of actin cytoskeleton;>>Pathogenic Escherichia coli infection;>>Salmonella infection
      • Gene Name:
      • CYFIP2
      • Protein Name:
      • CYFIP2
      • Human Swiss Prot No:
      • Q96F07
      • Mouse Swiss Prot No:
      • Q5SQX6
      • Immunogen:
      • Synthesized peptide derived from CYFIP2 at AA range: 1171-1220
      • Specificity:
      • CYFIP2 Polyclonal Antibody detects endogenous levels of CYFIP2
      • Formulation:
      • Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
      • Source:
      • Polyclonal, Rabbit,IgG
      • Dilution:
      • WB 1:500-2000, ELISA 1:10000-20000
      • Purification:
      • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
      • Concentration:
      • 1 mg/ml
      • Storage Stability:
      • -15°C to -25°C/1 year(Do not lower than -25°C)
      • Other Name:
      • Cytoplasmic FMR1-interacting protein 2 (p53-inducible protein 121)
      • Observed Band(KD):
      • 150+45kD
      • Background:
      • disease:Up-regulated significantly in CD4+ T lymphocytes from patients with multiple sclerosis (at protein level).,function:Involved in T-cell adhesion and p53-dependent induction of apoptosis. Does not bind RNA.,induction:By p53.,RNA editing:Partially edited. Editing appears to be brain-specific.,similarity:Belongs to the CYFIP family.,subcellular location:Highly expressed in the perinuclear region. Enriched in synaptosomes. Treatment with leptomycin-B triggers translocation to the nucleus.,subunit:Interacts with FMR1, FXR1 AND FXR2. Component of the WAVE1 complex composed of ABI2, CYFIP2, C3orf10/HSPC300, NCKAP1 and WASF1/WAVE1. CYFIP2 binds to activated RAC1 which causes the complex to dissociate, releasing activated WASF1. The complex can also be activated by NCK1.,
      • Function:
      • disease:Up-regulated significantly in CD4+ T lymphocytes from patients with multiple sclerosis (at protein level).,function:Involved in T-cell adhesion and p53-dependent induction of apoptosis. Does not bind RNA.,induction:By p53.,RNA editing:Partially edited. Editing appears to be brain-specific.,similarity:Belongs to the CYFIP family.,subcellular location:Highly expressed in the perinuclear region. Enriched in synaptosomes. Treatment with leptomycin-B triggers translocation to the nucleus.,subunit:Interacts with FMR1, FXR1 AND FXR2. Component of the WAVE1 complex composed of ABI2, CYFIP2, C3orf10/HSPC300, NCKAP1 and WASF1/WAVE1. CYFIP2 binds to activated RAC1 which causes the complex to dissociate, releasing activated WASF1. The complex can also be activated by NCK1.,
      • Subcellular Location:
      • Cytoplasm . Nucleus . Cytoplasm, perinuclear region . Cell junction, synapse, synaptosome . Highly expressed in the perinuclear regionand enriched in synaptosomes (By similarity). Treatment with leptomycin-B triggers translocation to the nucleus (PubMed:17245118). .
      • Expression:
      • Expressed in T-cells. Increased expression is observed in CD4(+) T-lymphocytes from patients with multiple sclerosis (at protein level).
      • Products Images
      • Western Blot analysis of HEPG2 Hela cells using CYFIP2 Polyclonal Antibody diluted at 1:500. Secondary antibody(catalog#:RS0002) was diluted at 1:20000
      • Immunohistochemical analysis of paraffin-embedded human-tonsil, antibody was diluted at 1:200
      • Immunohistochemical analysis of paraffin-embedded human-tonsil, antibody was diluted at 1:200
      • Immunohistochemical analysis of paraffin-embedded human-colon, antibody was diluted at 1:200